MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
Pioneers: Triple Helix: New Business Models_Open Innovation, Virtual Organizations, Royalty Aggregators, Etc.
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Pfizer Inc. (NYSE: PFE)
Finance & Acquisition: Pfizer
Parents
Pfizer Inc. (NYSE: PFE)
Children
*Portfolio Companies: Pfizer Venture Systems
$51.3b (2005)
2005: Purchased by Pfizer for $530 million (2005)
2009: Pfizer Inc. acquired Wyeth in a cash and stock merger (2009)
2010: Pfizer completes FoldRX Acquisition (2010)
2011: Acura Pharmaceuticals Inc Receives 20 Million (2011)
2011: GlycoMimetics Inc Inks Licensing Deal Worth Up to $340 Million with Pfizer Inc. (PFE) (2011)
2012: $13 million Series B, Domain Associates, Roche Venture Fund, Pfizer Venture Investments
2012: Pfizer to Acquire NextWave for $700 Million (2012)
2013: We Have A Winner! Quick Take On The Humedica Acquisition By United Health (2013)
2014: GlycoMimetics collects $15M from Pfizer collaboration
2015: Pfizer grabs Hospira's biosims, generic injectables in $15B takeover
2015: Pfizer, Allergan Agree on Historic $150 Billion Merger Deal
2015: Pfizer, Allergan in final talks for all-stock deal worth a record-breaking $150B
2016: Pfizer backs out of $160B Allergan deal; White House scores victory
2016: Pfizer Shells Out $14B to Win Medivation Sweepstakes
2016: Pfizer, Moving on From Allergan, Pays $5.2B For Anacor Pharma
2017: Pfizer launches upstart with $103M, phase 3-ready drugs
2018: Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company
2018: Pfizer breaks off a 5-year, $635M collaboration deal with CytomX, with nothing to show for it – Endpoints News
2019: Array BioPharma's stock rockets after $11.4 billion buyout deal with Pfizer
2019: Array's colorectal cancer data shows why Pfizer splashed out $11B for the biotech
2019: Pfizer buys a rare disease biotech for $340M-plus, putting them on a path to compete with BioMarin – Endpoints News
2019: Pfizer Issues RFP for Addressing Gaps in Management of Primary Immunodeficiency Disorders
2019: Pfizer Issues RFP for Managing the IBD (irritable bowel disease) Patient
2019: Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field – Endpoints News
2019: Upjohn & Mylan to Merge, Freeing Pfizer to Focus on Biopharma R&D
2020: Addressing Racial Disparities in Cancer Care Competitive Grant Program - Request for Proposals (RFP)
2020: Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc. Nasdaq:FIXX
2020: Myovant and Pfizer Ink $4.2 Billion Deal for Orgovyx in Oncology and Women's Health_biospace
2020: Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
2020: Pfizer Issues RFP for 2021 Rheumatology Competitive Grant Program
2020: Pfizer Issues RFP for Artificial Intelligence/Machine Learning Research in Hemophilia
2020: Pfizer to funnel $500M into biotechs, offering 'crucial capital' during the COVID-19 crisis
2021: $500 million Pfizer Breakthrough Growth Initiative (PBGI)
2021: Pfizer Invites Applications for 2022 Fellowship for Inflammatory Dermatological Diseases
2021: Pfizer Issues RFP for Advances in Atopic Dermatitis for Dermatologists and Allergists
2021: Pfizer Issues RFP for Pre-clinical and Translational Research in Multiple Myeloma
2021: Pfizer scoops up Arena and its S1P drug in $6.7B buyout — chasing Bristol Myers and capping a lengthy biotech turnaround
2021: Pfizer to buy cancer drug developer Trillium in $2.3 bln deal
2021: Prostate Cancer Foundation, Pfizer Invite Applications for Health Equity Challenge Awards
2022 Pfizer (PFE)\ Investor Presentation - Slideshow_ seekingalpha.com
2022: Pfizer Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Pfizer to acquire Biohaven Pharma for $11.6 billion in cash sending Biohaven shares up 74% premarket
2022: Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
2022: Pfizer’s $5.4B GBT buy adds potential sickle cell disease ‘cure’ and former Sanofi candidates
2023: Astellas and Pfizer invite proposals to improve the quality of care for patients with prostate cancer
2023: Caribou stock soars as Pfizer invests $25M (NASDAQ:CRBU)
2023: How Pfizer’s $43 billion acquisition of Seagen could impact the biotech industry in Seattle_ geekwire
2023: Pfizer issues RFP for Improving Health Equity in IBD through Disparities Research
2023: Pfizer issues RFP for rapid education on drug-drug interactions in COVID-19 outpatient treatment
2025: Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio
2025: Pfizer revenue 2024
2025: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
2026: Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Anacor Pharmaceuticals (NASDAQ: ANAC)
Arena Pharmaceuticals (NASDAQ: ARNA)
Array BioPharma (NASDAQ: ARRY)
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN)
BioRexis Pharmaceuticals Corp
Celladon investors Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, GBS Venture Partners and Enterprise Partners Venture Capital, Johnson & Johnson Development Corp. and Venrock Associates.
Encysive Pharmaceuticals
Excaliard Pharmaceuticals Inc.
FoldRx Pharmaceuticals
Global Blood Therapeutics Inc. (NASDAQ: GBT)
Hospira Inc:#18. Medical Devices, $3.9B (2009)
Icagen, Inc. (ICGN)
King Pharmaceuticals
Medivation (NASDAQ: MDVN)
Metsera, Inc. (MTSR)
NextWave Pharmaceuticals
Pfizer Foundation (Global Medical Grants )
Pfizer Inc. Extends Tender Offer to Acquire King Pharmaceuticals®, Inc.
Pfizer Ventures
Pfizer:Acquisitions
Pharmacia, Inc.-CIMIT
PowderMed
ReViral Ltd
Seagen, Inc., Seattle Genetics (NASDAQ: SGEN)
Shareholders include Ventures West (25.8% pre-IPO stake), Johnson & Johnson Development Corp. (23.8%), Baker Brothers (12.9%), Pfizer Inc. (16.5%), Augment Investments (8.1%) and BC Advantage Fund (7.3%).
Therachon
Therachon Holding
Trillium Therapeutics (TRIL)
Jumps
*Key People: Pfizer
Organization & Developments: Pfizer